| Code | CSB-RA008541MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BI-1206, targeting FCGR2B (Fc gamma receptor IIB, also known as CD32B), an inhibitory Fc receptor expressed predominantly on B cells and myeloid cells. FCGR2B plays a critical regulatory role in humoral immunity by dampening B cell receptor signaling and antibody production through its immunoreceptor tyrosine-based inhibitory motif (ITIM). This receptor serves as a key checkpoint in immune homeostasis, and its dysfunction has been implicated in autoimmune disorders and B cell malignancies. In cancer contexts, FCGR2B expression on tumor-associated macrophages and malignant B cells contributes to immune evasion and tumor progression.
BI-1206 is a clinical-stage therapeutic antibody designed to block FCGR2B on tumor cells and immune cells within the tumor microenvironment, thereby enhancing antibody-dependent cellular cytotoxicity and phagocytosis. This biosimilar provides researchers with a valuable tool for investigating FCGR2B-mediated immune regulation, exploring combination immunotherapy strategies, and studying mechanisms of antibody therapeutic resistance in hematologic malignancies and solid tumors.
There are currently no reviews for this product.